RxDoctor Payments DataLook up a doctor →

Gus Gonzalez, MD

Hematology & Oncology · Edmond, OKNPI 1962497594

Payments from drug & device makers

$7,108in general payments, 2019–2025

Across 332 payments — averaging $21.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$693
  • Pfizer$454
  • Johnson & Johnson$443
  • AstraZeneca$436
  • Merck$374
  • Incyte Corporation$368
  • plus $4K from 54 others

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis37$693
Pfizer22$454
Johnson & Johnson(2 entities)25$443
AstraZeneca(2 entities)20$436
Merck20$374
Incyte Corporation14$368
Daiichi Sankyo Inc.11$300
Lilly USA, LLC14$298
Regeneron Healthcare Solutions, Inc.8$213
Amgen12$189
AbbVie7$173
GSK7$163
EMD Serono, Inc.6$144
Takeda Pharmaceuticals U.S.A., Inc.5$129
Bayer7$126
E.r. Squibb & Sons, L.L.C.7$116
Tempus AI, Inc5$111
Astellas Pharma US Inc1$100
Fennec Pharmaceuticals, Inc.4$98
Exelixis Inc.5$98
Array Biopharma Inc4$97
Eisai Inc.5$97
Sanofi6$95
Gilead(2 entities)3$84
Rigel Pharmaceuticals, Inc.4$82
Stemline Therapeutics Inc.3$72
Geron Corporation3$71
Kyowa Kirin, Inc.2$68
Genentech USA, Inc.4$65
Novocure Inc.3$63
Boehringer Ingelheim3$61
Legend Biotech USA Inc.2$61
Rhythm Pharmaceuticals, Inc.1$58
Pharmacosmos Therapeutics Inc.3$58
Menarini Silicon Biosystems, Inc.2$54
Azurity Pharmaceuticals, Inc.2$51
Iovance Biotherapeutics, Inc.2$51
Jazz Pharmaceuticals Inc.3$50
Tersera Therapeutics LLC2$50
AVEO Pharmaceuticals, Inc.2$49
Sobi, Inc2$47
Foundation Medicine, Inc.3$47
Karyopharm Therapeutics Inc.2$45
Sumitomo Pharma America, Inc.2$40
Janssen Scientific Affairs, LLC1$40
Pharmacyclics LLC, An Abbvie Company3$38
Agios Pharmaceuticals, Inc.2$38
Deciphera Pharmaceuticals Inc.1$35
Alnylam Pharmaceuticals Inc.2$34
Beone Medicines USA, Inc.1$32
Recordati_rare_diseases_inc.1$32
Intuitive Surgical1$31
Bristol Myers Squibb2$31
Ipsen Biopharmaceuticals, Inc1$27
Pharmaessentia USA Corporation1$26
Teva Pharmaceuticals USA, Inc.1$24
Beigene USA, Inc.1$23
Springworks Therapeutics, Inc.1$23
Progenics Pharmaceuticals, Inc.1$23
Seagen Inc.1$18

How this compares

$7,108 in reported general payments places this provider in the 55th percentile of 118 hematology & oncology providers in Oklahoma.

See all hematology & oncology providers in Oklahoma →

Medicare billing

Part B allowed, 2024
$113,389
Medicare patients
17
Services billed
3,541

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Edmond

See the full list for Oklahoma →

Where these figures come from

Is this you, or does something look wrong? →